Shanghai Fosun Pharmaceutical : APPROVAL FOR THE ISSUANCE OF CORPORATE BONDS IN THE PRC BY THE CHINA SECURITIES REGULATORY COMMISSION（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT

APPROVAL FOR THE ISSUANCE OF CORPORATE BONDS IN THE PRC

BY THE CHINA SECURITIES REGULATORY COMMISSION

Reference is made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') dated 31 March 2017 and 29 June 2017 and the circular of the Company dated 11 May 2017 (the ''Circular'') in relation to, among other things, the proposed public issuance of corporate bonds (the ''Corporate Bonds'') in the PRC. Unless otherwise specified, capitalised terms used herein shall have the same meanings as defined in the Circular.

Recently, the Company has received the Approval on the Public Issuance of the Corporate Bonds to the Qualified Investors by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Zheng Jian Xu Ke [2018] No. 265) (the ''Approval'') issued by China Securities Regulatory Commission (the ''CSRC'') dated 5 February 2018. Matters in relation to the issuance of Corporate Bonds are as follows:

• 1. CSRC has approved the Company to publicly issue the Corporate Bonds not exceeding RMB5.0 billion to qualified investors.

• 2. The Corporate Bonds shall be issued in tranches. The first tranche of issuance shall be completed within 12 months from the date of the CSRC's approval, and the remaining tranches of issuance shall be completed within 24 months from the date of the CSRC's approval.

• 3. The issuance of Corporate Bonds shall be carried out strictly in compliance with the application documents submitted to the CSRC.

• 4. The Approval shall be valid within 24 months from the date of the CSRC's approval.

• 5. From the date of the CSRC's approval to the date of completion of the issuance of Corporate Bonds, if any significant event occurs to the Company, the Company should forthwith report and to handle the same in accordance with the relevant rules.

The Company will proceed works related to the issuance of the Corporate Bonds in accordance with relevant laws and regulations, CSRC's approval and the authorization at the general meeting of the Company, and fulfil the disclosure obligations in a timely manner.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

9 February 2018

As at the date of this announcement, the executive Directors are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive Directors are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shui Kwan Danny.

* for identification purposes only